WO2011117377A2 - Improved methods and compositions for safe and effective treatment of erythema - Google Patents
Improved methods and compositions for safe and effective treatment of erythema Download PDFInfo
- Publication number
- WO2011117377A2 WO2011117377A2 PCT/EP2011/054596 EP2011054596W WO2011117377A2 WO 2011117377 A2 WO2011117377 A2 WO 2011117377A2 EP 2011054596 W EP2011054596 W EP 2011054596W WO 2011117377 A2 WO2011117377 A2 WO 2011117377A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- erythema
- topical
- brimonidine
- symptom
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Definitions
- Erythema is a skin condition characterized by redness of the skin. It occurs with any skin injury, infection, or inflammation. It can also occur as a reaction to medications, illness or emotions. It can further occur for reasons currently unknown. Erythema is difficult to treat. Currently available treatments for erythema mainly treat the underlying diseases and avoid known triggers. These treatments are of limited effectiveness, particularly for erythema with unknown causes.
- Brimonidine a selective a2-adrenergic agonist
- IOP intraocular pressure
- OHT ocular hypertension
- the most common side effects associated with brimonidine therapy are dry mouth, fatigue/drowsiness, headache, mild hyperemia, blurred vision and foreign body sensation.
- Hypertension, palpitations and syncope have been reported by less than 3% patients in clinical trials involving brimonidine ophthalmic treatment. See McGhie, Journal of the Pharmacy Society of Wisconsin, May/June 2001, at World Wide Web:
- results from the dose- ranging study in patients with glaucoma or ocular hypertension showed that although 0.5% (w/w) had higher efficacy in the early phase of treatment, the 0.5% (w/w) and 0.2% (w/w) had similar efficacy after two weeks of treatment, and that 0.5% (w/w) had more systemic and ocular side effects than 0.2% (w/w). See, e.g., Walters, Survey of Ophthalmology, 1996, 41 : S19-S26).
- Ophthalmic formulations containing 0.2% (w/w) brimonidine have been used for chronic
- brimonidine has been only used for acute therapy for the prevention of postoperative intraocular pressure spikes.
- ophthalmic formulations containing lower concentrations of brimonidine, e.g., 0.15% (w/w) or 0.1% (w/w) have been subsequently developed and used for chronic ophthalmic applications.
- Brimonidine has been reported to be useful in treating erythema caused by rosacea. See, e.g., U.S. Ser. No. 10/853,585 to DeJovin et al.
- 0.2% (w/w) brimonidine tartrate as the "high" dosage for treating erythema. See US 2009/0061020 to Theobald et al.
- a higher concentration of brimonidine such as about 0.3% (w/w) to about 10% (w/w) can now be used in improved methods and compositions for safe and effective treatment of erythema or a symptom associated therewith.
- embodiments of the present invention relate to a method of providing a safe and effective treatment of erythema or a symptom associated therewith in a subject.
- the method comprises topically administering to a skin area affected by the erythema or the symptom a topical composition, which comprises about 0.3% to about 10% by weight brimonidine and a pharmaceutically acceptable carrier, wherein the topical administration effects a serum or plasma profile of brimonidine having a mean C max of about 54 ⁇ 28 pg/mL or less and a mean AUCo-24hr of about 568 ⁇ 277 pg.hr/mL or less.
- embodiments of the present invention relate to a method of producing a packaged product for providing a safe and effective treatment of erythema or a symptom associated therewith in a subject.
- the method comprises:
- a topical composition comprising about 0.3% to about 10% by weight brimonidine and a pharmaceutically acceptable carrier;
- topical composition (2) devising instructions for topically administering the topical composition to a skin area affected by the erythema or the symptom to obtain the safe and effective treatment, and (3) providing the topical composition and the instructions in a unified package, wherein the topical administration effects a serum or plasma profile of brimonidine having a mean Cmax of about 54 ⁇ 28 pg/mL or less and a mean AUCo-24hr of about 568 ⁇ 277 pg.hr/mL or less.
- embodiments of the present invention relate to a topical gel composition for providing a safe and effective treatment of erythema or a symptom associated therewith in a subject.
- the topical gel composition comprises:
- topical administration of the topical gel composition to a skin area affected by the erythema or the symptom effects a serum or plasma profile of brimonidine having a mean C max of about 54 ⁇ 28 pg/mL or less and a mean AUCo-24hr of about 568 ⁇ 277 pg.hr/mL or less.
- the topical composition used in or encompassed by embodiments of the present invention comprises about 0.4% (w/w) to about 0.6% (w/w)
- the erythema is erythema of rosacea.
- Figure 1 illustrates composite success on Day 1, Day 15 and Day 29 after the initial treatment, using last observation carried forward (LOCF) approach in the intent to treat ( ⁇ ) population;
- LOCF last observation carried forward
- Figure 2 illustrates CEA success on Day 1 , Day 15 and Day 29 after the initial treatment, using LOCF approach in the ⁇ population
- Figure 3 illustrates PSA-5 success on Day 1, Day 15 and Day 29 after the initial treatment using LOCF approach in the ITT population.
- erythema or a symptom associated therewith is intended to encompass any type or classification of abnormal skin redness associated with or resulting from rosacea, e.g., erythema or a symptom associated therewith in a patient with rosacea.
- a major symptom of rosacea is erythema, which is a skin disorder that generally affects the cheeks, nose, chin, and forehead of a patient.
- erythema or a symptom associated therewith encompasses different degrees or grades of erythema or a symptom associated therewith, from mild to severe.
- erythema or a symptom associated therewith can be rated by a clinician based on Clinician's Erythema Assessment Score (CEA) on a scale from 0 to 4, with 0 being clear skin with no signs of erythema; 1 being almost clear, slight redness; 2 being mild erythema, definite redness; 3 being moderate redness; and 4 being severe redness.
- CEA Clinician's Erythema Assessment Score
- Erythema or a symptom associated therewith can also be rated by a patient based on Patient's Self Assessment (PSA, also called PSA-5 herein) on a scale from 0 to 4, with 0 being no redness; 1 being very mild redness; 2 being mild redness; 3 being moderate redness and 4 being severe redness.
- PSA Patient's Self Assessment
- a skin area that is affected by erythema or that is prone to be affected by erythema can be identified using any diagnostic signs or means known in the art, and can be treated by methods according to embodiments of the present invention.
- the efficacy of the treatment can be measured using method known in the art. For example, the efficacy can be measured by the grades of improvement as evaluated by CEA, PSA the combination of CEA and PSA, and the duration of the improvement.
- brimonidine refers to the compound (5-bromo-quinoxalin- yl)-(4,5-dihydro-lH- imidazol-2- -amine having the structure of formula (I):
- any pharmaceutically acceptable salt of the compound including, but not limited to, brimonidine tartrate.
- phrases "pharmaceutically acceptable salt(s)" means those salts of a compound of interest that are safe and effective for topical use in mammals and that possess the desired biological activity.
- Pharmaceutically acceptable salts include salts of acidic or basic groups present in the specified compounds.
- Pharmaceutically acceptable acid addition salts include, but are not limited to, hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzensulfonate, p-toluenesulfonate and pamoate (i.e., 1 ,1 '-methylene -bis-(2 -hydro xy-3-naphthoate)) salts.
- Suitable base salts include, but are not limited to, aluminum, calcium, lithium, magnesium, potassium, sodium, zinc, and diethanolamine salts.
- topically administrable composition means any formulation or composition which is pharmaceutically and/or cosmetically acceptable for topical delivery of the specified compounds according to embodiments of the invention.
- exemplary forms of formulation that can be used for topical administration in embodiments of the present invention include, but are not limited to, sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions and suspensions.
- topically administrable composition as used herein, also encompasses locally applied and locally acting formulations such as formulations for use with implants, injections, or patches.
- topically administrable composition will depend on several factors, including, but not limited to, the nature of the symptoms to be treated or prevented, the
- composition is intended to encompass a product comprising the specified ingredient in the specified amount, as well as any product which results, directly or indirectly, from combinations of the specified ingredient in the specified amount.
- the term "subject” means any animal, preferably a mammal, most preferably a human, to whom will be or has been administered compounds or topical formulations according to embodiments of the invention.
- a subject is in need of, or has been the object of observation or experiment of, treatment or prevention of erythema or a symptom associated therewith.
- the term "instructions" when used in the context of a packaged product includes a publication, a recording, a diagram or any other medium of expression which can be used to communicate the usefulness of the packaged product for its designated use.
- the instructions can, for example, be affixed to or included within a container for the packaged product.
- treatment refers to an amelioration, prophylaxis, or reversal of erythema or a symptom associated therewith, for example, by lessening or delaying the onset of the redness of the skin affected by the erythema or the symptom.
- a "safe and effective amount of brimonidine” means the amount of brimonidine that is effective to treat erythema or a symptom associated therewith, without causing unacceptable drug related adverse events, when administered to a subject.
- unacceptable drug related adverse events shall all mean harm or undesired outcome associated with or caused by a proposed use of a drug, and the harm or undesired outcome reaches such a severity that a regulatory agency deems the drug unacceptable for the proposed use.
- topical administration of a safe and effective amount of brimonidine such as a topical composition comprising about 0.3% to about 10% by weight of brimonidine, to a skin area affected by erythema or a symptom associated therewith, provides effective treatment of erythema or a symptom associated therewith, without causing unacceptable drug related adverse events.
- topical administration of a topical composition comprising increasing concentration of brimonidine to a skin area affected by erythema or a symptom associated therewith resulted in a clear dosage responsive increase in the efficacy and an increase in the systemic exposure.
- embodiments of the present invention relate to a method of providing a safe and effective treatment of erythema or a symptom associated therewith in a subject, comprising topically administering to a skin area affected by the erythema or the symptom a topical composition comprising about 0.3% to about 10% by weight brimonidine and a pharmaceutically acceptable carrier, wherein the topical administration effects a serum or plasma profile of brimonidine having a mean C max of about 54 ⁇ 28 pg/mL or less and a mean AUCo-24hr of about 568 ⁇ 277 pg.hr/mL or less.
- the mean C max and the mean AUCo-24hr correspond to the serum or plasma profile of brimonidine after ophthalmic treatment with 0.2% (w/w) brimonidine tartrate eye drops as recommended in the label of the ophthalmic product.
- the onset of noticeable effect i.e., at least 1 -grade improvement of the erythema or the symptom
- the noticeable effect is then progressed to maximum improvement, which includes 2-grade of improvement of the erythema or the symptom that lasts for a sustained period of time.
- the maximum improvement then declines to noticeable effect, which then disappears.
- the grades of improvement of the erythema or the symptom can be evaluated by Clinician's Erythema Assessment Score (CEA), a Patient's Self Assessment (PSA), or a combination of CEA and PSA.
- CEA Clinician's Erythema Assessment Score
- PSA Patient's Self Assessment
- the topical administration of a topical composition comprising about 0.3% (w/w) to about 10% (w/w) brimonidine to a skin area affected by erythema or a symptom associated therewith results in significantly more effective treatment of the erythema and the symptom than a vehicle control for reduction of facial erythema associated with rosacea as measured by a 12 hour success profile evaluated on both CEA and PSA scales, without causing any unacceptable adverse effect.
- the 12 hour success profile comprises at least 1 -grade improvement of the erythema or the symptom.
- the topical administration of a topical composition comprising about 0.3% (w/w) to about 10% (w/w) brimonidine to a skin area affected by erythema or a symptom associated therewith resulted in significantly more reduction of facial erythema associated with rosacea compared to a vehicle control as measured by a 12 hour success profile evaluated on both CEA and PSA scales, without causing any unacceptable adverse effect.
- the 12 hour success profile comprises a noticeable effect of 1 -grade improvement of the erythema or the symptom and about 1 hour to about 8 hours of a 2-grade improvement of the erythema or the symptom.
- the 2-grade improvement lasts, for example, at least about 6 hours, at least about 5 hours, at least about 4 hours, at least about 3 hours, at least about 2 hours or at least about 1 hour, depending on the applied dose, the particular subject, the severity and complications of erythema being treated, etc.
- the 12 hour success profile comprises a noticeable effect of 1 -grade improvement of the erythema or the symptom and about 2 hours to about 7 hours of a 2-grade improvement of the erythema or the symptom.
- the 12 hour success profile comprises a noticeable effect of 1 -grade improvement of the erythema or the symptom and about 3 hours to about 6 hours of a 2-grade improvement of the erythema or the symptom.
- the 12 hour success profile comprises a noticeable effect of 1 -grade improvement of the erythema or the symptom and about 2 hours to about 5 hours of a 2-grade improvement of the erythema or the symptom.
- the erythema is erythema of rosacea.
- the topically administrable composition comprises about 0.3%, 0.5%, 1.0%, 1.5%, 2.0%, 2.5%, 3.0%, 3.5%, 4.0%, 4.5%, 5.0%, 5.5%, 6.0%, 6.5%, 7.0%, 7.5%, 8.0%, 8.5%, 9.0%, 9.5% or 10.0%, by weight of brimonidine, such as brimonidine tartrate.
- brimonidine such as brimonidine tartrate.
- the topically administrable composition comprises about 0.4%, about 0.45%, about 0.5%, about 0.55% or about 0.6%, by weight of brimonidine, such as brimonidine tartrate.
- the topical composition comprises about 0.5% by weight of brimonidine, such as about 0.5% by weight of brimonidine tartrate.
- the topically administrable compositions of the invention can be topically applied directly to the affected area in any conventional manner known in the art, e.g., by dropper, applicator stick, or cotton swab, as a mist via an aerosol applicator, via an intradermal or transdermal patch, or by simply spreading a formulation of the invention onto the affected area with fingers, a sponge, a pad, or wipes.
- the amount of a topical formulation of the invention applied to the affected skin area ranges from about 0.0001 g/cm of skin surface area to about 0.05 g/cm 2 , preferably, 0.002 g/cm 2 to about 0.005 g/cm 2 of skin surface area.
- one to four applications per day are recommended during the term of treatment.
- the topical composition is topically applied to the affected skin area once daily.
- Methods of the present invention can be used in conjunction with one or more other treatments and medications for erythema or a symptom associated therewith, such as the
- medications used to treat the underlying disease that causes erythema that causes erythema, antihistamines to control itching, antibiotics, corticosteroids, intravenous immunoglobulins, acetaminophen, etc.
- the other medicament or treatment can be administered to the subject simultaneously with, or in a sequence and within a time interval of, the administration of brimonidine, such that the active ingredients or agents can act together to treat or prevent erythema and symptoms associated therewith.
- the other medicament or treatment and brimonidine can be administered in the same or separate formulations at the same or different times, i.e., before or after. Any suitable route of administration can be employed to deliver the additional treatment or medication.
- Another aspect of the invention relates to a packaged product for providing a safe and effective treatment of erythema or a symptom associated therewith in a subject.
- the method comprises:
- a topical composition comprising about 0.3% to about 10% by weight brimonidine and a pharmaceutically acceptable carrier;
- the topical composition is contained within one suitable container, such as a dropper, ajar, or a tube with a suitable small orifice size, such as an extended tip tube, made of any pharmaceutically suitable material.
- the topical formulations according to embodiments of the invention can be filled and packaged into a plastic squeeze bottle or tube.
- Suitable container-closure systems for packaging a topical formulations of the invention are commercially available for example, from Wheaton Plastic Products, 1 101 Wheaton Avenue, Millville, N.J. 08332.
- an applicator can be provided in or attached to the container, or separately from the container.
- the instructions are, for example, a pamphlet or package label.
- the instructions explain how to administer topical formulations of the invention, in an amount and for a period of time sufficient to provide a safe and effective treatment of erythema or a symptom associated therewith.
- the instructions include, for example, the dosage and administration instructions, the topical formulation's composition, the clinical pharmacology, drug resistance, pharmacokinetics, absorption, bioavailability, and contraindications.
- Topical gel composition for providing a safe and effective treatment of erythema or a symptom associated therewith in a subject.
- the topical gel composition comprises:
- the topical administration of the topical gel composition to a skin area affected by the erythema or the symptom effects a serum or plasma profile of brimonidine having a mean C max of about 54 ⁇ 28 pg/mL or less and a mean AUCo-24hr of about 568 ⁇ 277 pg.hr/mL or less.
- the topically administrable composition are prepared by mixing a pharmaceutically acceptable carrier with the safe and effective amount of brimonidine according to known methods in the art, for example, methods provided by standard reference texts such as, REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY 1577-1591 , 1672-1673, 866-885(Alfonso R.
- the topical gel composition comprises about 0.4% to about 0.6% by weight of brimonidine, more preferably, 0.5% by weight of brimonidine tartrate.
- Suitable gelling agents known in the art can be used in the present invention.
- suitable gelling agents are disclosed in REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY 1517-1518 (Alfonso R. Gennaro ed. 19th ed. 1995), which is hereby incorporated herein by reference.
- the gelling agents used in embodiments of the present invention include, but are not limited to, one or more hydrophilic and hydroalcoholic gelling agents used in the cosmetic and pharmaceutical industries.
- the hydrophilic or hydroalcoholic gelling agent comprises "CARBOPOL®” (B.F. Goodrich, Cleveland, Ohio), "HYP AN®” (Kingston Technologies, Dayton, N.J.),
- NATROSOL® (Aqualon, Wilmington, Del), “KLUCEL®” (Aqualon, Wilmington, Del), or “STABILEZE®” (ISP Technologies, Wayne, N.J.).
- the preferred compositional weight percent range for “CARBOPOL®” is between about 0.5% to about 2%, while the preferred weight percent range for "NATROLSOL®” and “KLUCEL®” is between about 0.5% to about 4%.
- the preferred compositional weight percent range for both “HYP AN®” and “STABILEZE®” is between 0.5% to about 4%.
- Other preferred gelling agents include hydroxyethylcellulose, cellulose gum, MVE/MA decadiene crosspolymer, PVM/MA copolymer, glycerine polyacrylate, or a combination thereof.
- Examples of carbomers that can be used in the present invention include, but are not limited to, Carbomer 910, 934P, 940, 941, 980 and 1342, and Carbopol® 974P and Carbopol® 980.
- the carbomer is Carbomer 934P or Carbopol® 974P, and Carbopol® 980.
- the amount of the carbomer in the composition is about 0.5%, 0.6%, 0.7%, 0.8%, 0.85%, 0.95%, 1.05%, 1.15%, 1.25%, 1.35%, 1.45%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9% or 2.0% (w/w).
- Polyol gel formulations with various ingredients solubilized therein have been used to minimize irritation when applied to the skin of a subject, while ensuring bioavailability of the active agent in the formulation. See Other III et al. "Gels and Jellies," pp. 1327-1344 of Encyclopedia of Pharmaceutical Technology, vol. 3 (ed. by Swarbrick, et al, pub.
- formulations can serve one or more functions such as solubilizing agents, moisturizers, emollients, skin humectant, skin-penetration agents, etc.
- Suitable polyols that can be used in embodiments of the present invention include, but are not limited to, glycerine, propylene glycol, dipropylene glycol, hexylene glycol, butylene glycol, and liquid polyethylene glycols, such as polyethylene glycol 200 to 600.
- the amount of the total polyols in the composition is about 5.0% to 30.0% (w/w), for example, about 5.0%, 5.5%, 6.0%, 6.5%, 7.0%, 7.5%, 8.0%, 8.5%, 9.0%, 9.5%, 10.0%, 10.5%, 11.0%, 11.5%, 12.0%, 12.5%, 13.0%, 13.5%, 14.0%, 14.5%, 15.0%, 17%, 20%, 25% or 30% (w/w).
- the topical gel composition comprises a first polyol and a second polyol, such as propylene glycol and glycerine, respectively.
- the amount of each of the first and second polyols in the composition is independently about 4 to 15%, such as 4.5% to 6.5% (w/w), for example, 4.5%, 5.0%, 5.5%, 6.0% or 6.5% (w/w).
- the pH of the topical formulations of the invention are preferably within a
- physiologically acceptable pH e.g., within the range of about 4 to about 8, preferably, of about 6 to about 7.5, and more preferably about 4.5 to 6.5.
- an effective amount of a buffer is included.
- the buffering agent is present in the aqueous topical formulation in an amount of from about 0.05 to about 1 weight percent of the formulation.
- the topical gel composition of the present invention can include one or more other ingredients, such as a protective agent, a cosmetic agent, an adsorbent, a preservative, an antioxidant, a surfactant, a skin-penetration agent, local anesthetics, analgesics etc.
- a protective agent such as a cosmetic agent, an adsorbent, a preservative, an antioxidant, a surfactant, a skin-penetration agent, local anesthetics, analgesics etc.
- a topical gel composition according to embodiments of the invention further comprises water dispersible form of titanium dioxide (Ti02), preferably at an amount that is sufficient to mask the color of brimonidine or another colored ingredient in the formulation, but would not cause irritation to the skin.
- Ti02 may cause mild irritation and reddening to the eyes, thus eye contact with the Ti02 - containing topically administrable composition should be avoided.
- Titanium dioxide imparts a whiteness to the topically administrable composition and helps to increase the opacity and reduce the transparency of the composition. Titanium dioxide absorbs, reflects, or scatters light (including ultraviolet radiation in light), which can help protect products from deterioration. Titanium dioxide can also be used as a sunscreen to protect the user from the harmful effects of ultraviolet radiation that is part of sunlight.
- the amount of water dispersible form of titanium dioxide in the composition is about 0.04 to 0.2%, such as 0.04%, 0.0425%,
- Suitable preservatives include, but are not limited to, quaternary ammonium compounds, such as benzalkonium chloride, benzethonium chloride, cetrimide, dequalinium chloride, and cetylpyridinium chloride; alcoholic agents, for example, chlorobutanol, phenylethyl alcohol, and benzyl alcohol; parabens such as methylparaben, ethylparaben, propylparaben, and butylparaben; antibacterial esters, for example, esters of parahydroxybenzoic acid; and other anti-microbial agents such as chlorhexidine, chlorocresol, benzoic acid, polymyxin, and phenoxyethanol.
- the preservative is selected from the group consisting of sodium benzoate, phenoxyethanol, benzyl alcohol, methylparaben, imidazolidinyl urea and diazolidinyl urea.
- the topically administrable composition according to embodiments of the invention can optionally include one or more other pharmaceutically active ingredients, including, but not limited to, medications used to treat the underlying disease that causes erythema, antihistamines to control itching, antibiotics, corticosteroids, intravenous immunoglobulins, acetaminophen, etc.
- other pharmaceutically active ingredients including, but not limited to, medications used to treat the underlying disease that causes erythema, antihistamines to control itching, antibiotics, corticosteroids, intravenous immunoglobulins, acetaminophen, etc.
- the pH of the formulation is adjusted to about 4.5 to 7.0.
- Carbomer 934P 1.25% 1.0% 1.5%
- This study was a randomized, evaluator-blinded, intra-individual comparative pharmacokinetic study of brimonidine tartrate, ophthalmic solution (0.2%) and topical gel (0.07%, 0.18% and 0.50%) applied under maximal use conditions for 29 days in subjects with moderate to severe erythema associated with rosacea.
- Major entrance criteria included clinical diagnosis of moderate to severe facial erythema associated with rosacea, CEA score >3, and IOP level 11 -21 mmHg.
- Intra-subject comparison of topical to ophthalmic exposure following one day treatment with brimonidine tartrate ophthalmic solution 0.2% was performed.
- a total of 102 subjects were randomized: 24, 26, 25, and 27 subjects in 0.5% Gel QD, 0.18% Gel BID, 0.18% Gel QD, and 0.07% Gel BID, respectively.
- On the Day 1 visit one drop of brimonidine tartrate ophthalmic solution 0.2% was administered to each eye every 8 hours over a 24 hour period.
- one gram of topical gel (0.07%, 0.18%, or 0.50% of brimonidine tartrate) was applied once (QD) or twice daily (BID) to the face of subjects for 4 weeks.
- Blood samples for complete PK profiling were taken during the 24-hour ocular treatment (study Day 1) and during the first day of topical application (study Day 4), fifteen days of topical application (study Day 18) and after the last topical application up to 72 hours post-dose (study Day 32). Additional blood samples were collected before application (Day 10, Day 24). Brimonidine plasma concentrations were determined by using a validated LC-MS/MS method with a lower limit of quantification (LOQ) of 10 pg/mL.
- LOQ lower limit of quantification
- PK parameters for brimonidine were calculated using standard non-compartmental method and C max , AUCo-24hr were analyzed statistically using log-transformed data. For both the differences between times administration routes and between treatment groups, the limits of the intervals were back-transformed into exponential to obtain 90% confidence intervals (90% CI) of the ratios of geometric means on the original scale. The statistical analysis was performed using all Cmax (BLQ values being replaced by the LOQ) and using only quantifiable AUCo-24hr.
- Ocular treatment Administration of brimonidine tartrate 0.2% by ophthalmic route resulted in quantifiable exposure (>10 pg/mL) in all patients receiving TID treatment.
- the pharmacokinetic (PK) parameters of the ophthalmic solution have a mean C max of 54 ⁇ 28 pg/mL (range: 16 -134 pg/mL) and a mean AUCo-24hr Of 568 ⁇ 277 pg.hr/mL (range: 124 - 1490 pg.hr/mL).
- Topical treatments Daily topical application of brimonidine Gel for 29 days resulted in quantifiable (> 10 pg/mL) systemic exposure in 24%, 48%, 68% and 75% of subjects receiving brimonidine Gel 0.07 % BID, 0.18 % QD, 0.18 % BID or 0.5% QD, respectively.
- the mean ( ⁇ SD) C max were 13 ⁇ 9 pg/mL 17 ⁇ 20 pg/mL, 17 ⁇ 10 pg/mL, 25 ⁇ 24 pg/mL for brimonidine Gel 0.07 % BID, 0.18 % QD, 0.18 % BID or 0.5% QD, respectively.
- Quantifiable AUC 0 - 2 4hr were 172 ⁇ 87 pg.hr/mL, 183 ⁇ 1 13 pg.hr/mL, 267 ⁇ 1 19 pg.hr/mL, 364 ⁇ 216 pg.hr/mL for brimonidine Gel 0.07 % BID, 0.18 % QD, 0.18 % BID or
- the Ocular/Topical ratios calculated over the entire duration of the topical treatment period were significantly lower than 1.
- the C max mean ratio was 0.2 for 0.07 % BID group, ranged from 0.2 to 0.3 for 0.18 % QD and BID groups and ranged from 0.3 to 0.6 for 0.5 % QD group.
- the upper limit of the 90 % confidence interval did not include 0.8 whatever the dose and dose regimen tested.
- concentrations of brimonidine higher than 0.2% (w/w) can be used for topical administration to an affected skin area for safe and effective treatment of a skin disorder.
- Major entrance criteria included clinical diagnosis of moderate to severe facial erythema associated with Rosacea, CEA score >3 and PSA-5 score >3, presence of no more than 2 facial lesions, and IOP level at least 10 mmHg.
- Qualified subjects were randomized in a 1 :1 :1 :1 :1 ratio (block size of 5) to one of the five treatment arms (0.5% QD, 0.18% BID, 0.18% QD, Vehicle BID, Vehicle QD).
- a total of 269 subjects from 17 clinical sites were randomized to Topical Gel or Vehicle Gel: 53, 54, 54, 53, and 55 subjects in the 0.5% QD, 0.18% BID, 0.18% QD, Vehicle BID, and Vehicle QD arms, respectively. All 269 subjects were included in the ITT and Safety population, and 237 subjects were included in the PP population.
- CEA and PSA evaluation data were collected at each clinic visit at Hours 3, 6, 9, and 12 after study drug application. Data collected at 30 minutes after study drug application comprised the secondary endpoints of CEA Initial Effect and PSA Initial Effect. Subject-reported efficacy data were collected at clinic visits and on non-clinic days during the treatment period. Safety were assessed throughout the study.
- the primary endpoint, Composite Success is defined as a 2-grade improvement on both CEA and PSA-5 measured at Hours 3, 6, 9 and 12 on Day 29 after the treatment. Statistical analysis was performed to compare each active treatment (0.5% QD, 0.18% BID and QD) vs. the
- CEA-Success and PSA-5 Success were also analyzed individually.
- the magnitudes of the CEA-Success ( Figure 2) and PSA-5 ( Figure 3) Success were greater in all treatment groups compared to Composite Success but the pattern of the relative effects was same as observed in Composite Success. Consistently, 0.5% QD showed the greatest effect for CEA
Abstract
Description
Claims
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2792646A CA2792646C (en) | 2010-03-26 | 2011-03-25 | Improved uses and compositions for safe and effective treatment of erythema |
ES11710199.8T ES2627405T3 (en) | 2010-03-26 | 2011-03-25 | Compositions comprising brimonidine for the treatment of erythema |
RU2012145616/15A RU2519676C1 (en) | 2010-03-26 | 2011-03-25 | Advanced methods and compositions for safe and effective treatment of erythema |
JP2013500520A JP5747391B2 (en) | 2010-03-26 | 2011-03-25 | Improved methods and compositions for safe and effective treatment of erythema |
KR1020177003732A KR20170018974A (en) | 2010-03-26 | 2011-03-25 | Improved methods and compositions for safe and effective treatment of erythema |
BR112012024289A BR112012024289A2 (en) | 2010-03-26 | 2011-03-25 | "Method to Provide Safe and Effective Treatment of Erythema and Topical Gel Composition" |
DK11710199.8T DK2552449T3 (en) | 2010-03-26 | 2011-03-25 | COMPOSITIONS INCLUDING BRIMONIDINE FOR TREATMENT OF ERYTHEM |
KR1020157010973A KR20150055082A (en) | 2010-03-26 | 2011-03-25 | Improved methods and compositions for safe and effective treatment of erythema |
CN201180025974XA CN103298472A (en) | 2010-03-26 | 2011-03-25 | Improved methods and compositions for safe and effective treatment of erythema |
MX2012010824A MX2012010824A (en) | 2010-03-26 | 2011-03-25 | Improved methods and compositions for safe and effective treatment of erythema. |
KR1020127027976A KR101707704B1 (en) | 2010-03-26 | 2011-03-25 | Improved methods and compositions for safe and effective treatment of erythema |
AU2011231543A AU2011231543B2 (en) | 2010-03-26 | 2011-03-25 | Improved methods and compositions for safe and effective treatment of erythema |
US13/637,040 US20130071489A1 (en) | 2010-03-26 | 2011-03-25 | Methods and compositions for safe and effective treatment of erythema |
EP11710199.8A EP2552449B1 (en) | 2010-03-26 | 2011-03-25 | Compositions comprising brimonidine for the treatment of erythema |
US14/097,912 US20140094469A1 (en) | 2010-03-26 | 2013-12-05 | Methods and compositions for safe and effective treatment of erythema |
US14/679,598 US9861631B2 (en) | 2010-03-26 | 2015-04-06 | Methods and compositions for safe and effective treatment of erythema |
US14/968,104 US9861632B2 (en) | 2010-03-26 | 2015-12-14 | Methods and compositions for safe and effective treatment of erythema |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28275410P | 2010-03-26 | 2010-03-26 | |
US61/282,754 | 2010-03-26 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/637,040 A-371-Of-International US20130071489A1 (en) | 2010-03-26 | 2011-03-25 | Methods and compositions for safe and effective treatment of erythema |
US14/097,912 Continuation US20140094469A1 (en) | 2010-03-26 | 2013-12-05 | Methods and compositions for safe and effective treatment of erythema |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011117377A2 true WO2011117377A2 (en) | 2011-09-29 |
WO2011117377A3 WO2011117377A3 (en) | 2013-01-10 |
Family
ID=44012352
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2011/054596 WO2011117377A2 (en) | 2010-03-26 | 2011-03-25 | Improved methods and compositions for safe and effective treatment of erythema |
Country Status (16)
Country | Link |
---|---|
US (6) | US20130071489A1 (en) |
EP (1) | EP2552449B1 (en) |
JP (1) | JP5747391B2 (en) |
KR (3) | KR20150055082A (en) |
CN (2) | CN106038476B (en) |
AU (1) | AU2011231543B2 (en) |
BR (1) | BR112012024289A2 (en) |
CA (1) | CA2792646C (en) |
DK (1) | DK2552449T3 (en) |
ES (1) | ES2627405T3 (en) |
HU (1) | HUE033143T2 (en) |
MX (1) | MX2012010824A (en) |
PL (1) | PL2552449T3 (en) |
PT (1) | PT2552449T (en) |
RU (1) | RU2519676C1 (en) |
WO (1) | WO2011117377A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013010032A1 (en) * | 2011-07-14 | 2013-01-17 | Allergan, Inc. | Gel compositions of oxymetazoline and methods of use |
JP2014533271A (en) * | 2011-11-10 | 2014-12-11 | アラーガン インコーポレイテッドAllergan,Incorporated | Pharmaceutical composition for treating skin diseases and conditions comprising 7- (1H-imidazol-4-ylmethyl) -5,6,7,8-tetrahydroquinoline |
US10201535B2 (en) | 2011-11-10 | 2019-02-12 | Allergan, Inc. | Pharmaceutical compositions comprising 7-(1H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions |
WO2020044136A1 (en) * | 2018-08-29 | 2020-03-05 | Cellix Bio Private Limited | Ophthalmic compositions and methods for the treatment of eye disorders and skin diseases |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8410102B2 (en) * | 2003-05-27 | 2013-04-02 | Galderma Laboratories Inc. | Methods and compositions for treating or preventing erythema |
US7439241B2 (en) * | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
WO2011053487A1 (en) * | 2009-10-26 | 2011-05-05 | Galderma Pharma S.A. | Methods of treating or preventing acute erythema |
WO2011117377A2 (en) | 2010-03-26 | 2011-09-29 | Galderma Research & Development | Improved methods and compositions for safe and effective treatment of erythema |
ES2730411T3 (en) | 2010-03-26 | 2019-11-11 | Galderma Res & Dev | Enhanced compositions comprising brimonidine for a safe and effective treatment of telangiectasia |
CN104288768A (en) * | 2010-06-30 | 2015-01-21 | 盖尔德马研究及发展公司 | Use of alpha-adrenergic receptor agonist |
BR112013009578B1 (en) | 2010-10-21 | 2020-10-20 | Galderma S.A. | topical gel composition and use of a topical gel composition |
RU2014119879A (en) | 2011-10-19 | 2015-11-27 | Галдерма С.А. | METHOD FOR REDUCING BLOOD TIDGE TO FACE WITH SYSTEMATIC USE OF PHOSPHODESTERASE TYPE 5 INHIBITORS |
WO2020222192A1 (en) | 2019-05-01 | 2020-11-05 | Clexio Biosciences Ltd. | Methods of treating pruritus |
CA3137267A1 (en) | 2019-05-01 | 2020-11-05 | Clexio Biosciences Ltd. | Methods of treating pruritus |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090061020A1 (en) | 2007-08-31 | 2009-03-05 | Theobald Klaus P | Brimonidine Compositions for Treating Erythema |
Family Cites Families (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3278447A (en) | 1963-12-02 | 1966-10-11 | Cloro Bac Products Inc | Process for stabilizing chlorine dioxide solution |
US3560501A (en) | 1966-09-15 | 1971-02-02 | Ciba Geigy Corp | Process for making dihydroquinazolines |
BG16042A3 (en) | 1968-11-12 | 1972-05-20 | Nans Ott | METHOD FOR OBTAINING NEW 2(1H)-QUINAZOLINONES |
US3594380A (en) | 1969-02-18 | 1971-07-20 | American Home Prod | Isoquinolin-1(2h)-ones |
BE766039A (en) | 1971-04-21 | 1971-09-16 | Labofina Sa | NEW POLYMERS CONTAINING PYRAZOLE UNITS AND PROCESS FOR PREPARING THESE POLYMERS. |
US3740442A (en) | 1972-01-14 | 1973-06-19 | Sandoz Ag | 2-isopropylaminobenzophenones in treating inflammation |
BE795970A (en) | 1972-02-29 | 1973-08-27 | Pfizer | NEW DERIVATIVES OF QUINOLEINE, QUINOXALINE AND QUINAZOLINE ER PHARMACEUTICAL COMPOSITION CONTAINING THEM |
US4029792A (en) | 1972-02-29 | 1977-06-14 | Pfizer Inc. | (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents |
US4164570A (en) | 1973-09-24 | 1979-08-14 | David Clough | Stabilized aqueous catecholamine solutions |
DE2436882A1 (en) | 1974-07-29 | 1976-02-19 | Schering Ag | NEW OXYPHENYLBUTAZONE DERIVATIVES AND THEIR PRODUCTION |
DE2436883C2 (en) | 1974-07-29 | 1985-08-22 | Schering AG, 1000 Berlin und 4709 Bergkamen | Benzimidazole derivatives, processes for their preparation and pharmaceuticals containing them |
DE2632678C2 (en) | 1976-07-16 | 1986-02-27 | Schering AG, 1000 Berlin und 4709 Bergkamen | 6α-Fluoro-12α-Halo-Corticoids and Process for Their Preparation |
NZ185295A (en) | 1976-10-04 | 1980-04-28 | Schering Ag | 9-chloroprednisolone derivatives and pharmaceutical compositions |
US4201211A (en) | 1977-07-12 | 1980-05-06 | Alza Corporation | Therapeutic system for administering clonidine transdermally |
US4285967A (en) | 1978-06-30 | 1981-08-25 | Estee Lauder Inc. | Cosmetic preparation for reducing redness of blemishes |
US4256763A (en) | 1978-09-19 | 1981-03-17 | Mchugh John E | Treatment of herpes simplex infections and acne |
US5166331A (en) | 1983-10-10 | 1992-11-24 | Fidia, S.P.A. | Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same |
US4908387A (en) | 1988-06-06 | 1990-03-13 | The Regents Of The University Of California | Use of beta2 antagonists in the treatment of inflammatory diseases, in particular, rheumatoid arthritis |
IL92351A (en) | 1988-11-29 | 1994-02-27 | Allergan Inc Irvine | Aqueous opthalmic solutions containing stabilized chlorine dioxide and an inorganic salt |
FR2648709A1 (en) | 1989-06-23 | 1990-12-28 | Boehringer Ingelheim France | NOVEL USE OF 1-PHENYL-2-AMINOETHANOL DERIVATIVES AS HEALING MEANS |
US5112822A (en) | 1989-10-12 | 1992-05-12 | Allergan, Inc. | (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same |
US5198442A (en) | 1989-10-12 | 1993-03-30 | Allergan, Inc. | (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same |
US5077292A (en) | 1989-10-12 | 1991-12-31 | Allergan, Inc. | (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same |
US5326763A (en) | 1989-10-12 | 1994-07-05 | Allergan, Inc. | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
US5204347A (en) | 1989-10-12 | 1993-04-20 | Allergan, Inc. | Methods for using (2-imidazolin-2-ylamino) tetrahydroquinoxalines |
US5021416A (en) | 1989-10-31 | 1991-06-04 | Allergan, Inc. | Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure |
US5130441A (en) | 1990-02-06 | 1992-07-14 | Allergan, Inc. | Method for producing amino-2-imidazoline derivatives |
US5237072A (en) | 1990-02-06 | 1993-08-17 | Allergan, Inc. | Method for producing amino-2-imidazoline derivatives |
GB9010526D0 (en) * | 1990-05-10 | 1990-07-04 | Unilever Plc | Cosmetic composition |
US5721237A (en) | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
US5736165A (en) | 1993-05-25 | 1998-04-07 | Allergan | In-the-eye use of chlorine dioxide-containing compositions |
US6323204B1 (en) | 1993-10-13 | 2001-11-27 | Allergan | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
ES2187533T3 (en) | 1993-10-13 | 2003-06-16 | Allergan Inc | USDO DERIVATIVES OF (2-IMIDAZOLIN-2-ILAMINO) QUINOXALINA. |
US6117871A (en) | 1993-12-17 | 2000-09-12 | The Procter & Gamble Company | 6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists |
WO1996013267A2 (en) | 1994-10-27 | 1996-05-09 | Allergan | Combinations of prostaglandins and brimonidine or derivatives thereof for the treatment of glaucoma |
US6294563B1 (en) | 1994-10-27 | 2001-09-25 | Allergan Sales, Inc. | Combinations of prostaglandins and brimonidine or derivatives thereof |
WO2000023066A2 (en) | 1998-10-20 | 2000-04-27 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain and inflammation |
US5693646A (en) | 1994-12-22 | 1997-12-02 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
WO1996025163A1 (en) | 1995-02-14 | 1996-08-22 | Board Of Supervisors Or Louisiana State Universityof Agricultural And Mechanical College Through Itsmedical Center | Treatment of herpes simplex viruses |
FR2732221B1 (en) | 1995-03-28 | 1997-04-25 | Oreal | USE OF A CGRP ANTAGONIST TO TREAT CUTANEOUS REDNESS OF NEUROGENIC ORIGIN AND COMPOSITION OBTAINED |
US6194415B1 (en) | 1995-06-28 | 2001-02-27 | Allergan Sales, Inc. | Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury |
CA2154979A1 (en) | 1995-07-28 | 1997-01-29 | Kenneth T. Armstrong | Topical phenylephrine preparation |
US5720962A (en) | 1995-10-04 | 1998-02-24 | Au Pharmaceuticals, Inc. | Analgesic lotion for hemorrhoids and method of making such lotion |
US6441047B2 (en) | 1995-11-17 | 2002-08-27 | Alcon Manufacturing Ltd.. | Combination therapy for treating glaucoma |
US5910312A (en) | 1996-10-09 | 1999-06-08 | Ideal Ideas, Inc. | Acne treatment composition with vasoconstrictor |
US5753637A (en) | 1996-10-09 | 1998-05-19 | Ideal Ideas, Inc. | Method of treating acne conditions |
US5916574A (en) | 1996-10-09 | 1999-06-29 | Ideal Ideas, Inc. | Method of treating natural poison skin conditions |
US5888493A (en) | 1996-12-05 | 1999-03-30 | Sawaya; Assad S. | Ophthalmic aqueous gel formulation and related methods |
WO1998036730A2 (en) | 1997-02-21 | 1998-08-27 | Beiersdorf Ag | Compositions for treating acne rosacea |
US6007846A (en) | 1997-05-16 | 1999-12-28 | Townley Jewelry, Inc. | Scented body gel having particulate matter in the form of glitter with predetermined shapes |
FR2767691B1 (en) | 1997-08-27 | 2000-02-18 | Oreal | USE OF A LIPID VEHICLE-BASED DISPERSION AS AN ANTI-INFLAMMATORY COMPOSITION |
US6159944A (en) | 1998-02-27 | 2000-12-12 | Synchroneuron, Llc | Method for treating painful conditions of the anal region and compositions therefor |
CA2323451C (en) | 1998-03-11 | 2013-01-08 | Kabushiki Kaisha Soken | Skin conditioner |
US6432934B1 (en) | 1998-08-06 | 2002-08-13 | Advanced Vision Research | Methods and compositions for topical treatment of eye surface inflammation and related dry eye disease |
US20030087962A1 (en) | 1998-10-20 | 2003-05-08 | Omeros Corporation | Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation |
US20020197300A1 (en) | 1999-02-22 | 2002-12-26 | Schultz Clyde L. | Drug delivery system for anti-glaucomatous medication |
SE9901295D0 (en) | 1999-04-13 | 1999-04-13 | Jan Hedner | Methods and means for preventing, treating and diagnosing cardiovascular complications in patients with obstructive sleep apnea |
AU5331200A (en) | 1999-06-11 | 2001-01-02 | Ohio State University Research Foundation, The | Methods and compositions for treating raynaud's phenomenon and scleroderma |
WO2001013955A1 (en) | 1999-08-19 | 2001-03-01 | Lavipharm S.A. | Film forming polymers, methods of use, and devices and applications thereof |
US6147102A (en) | 1999-10-26 | 2000-11-14 | Curatek Pharmaceuticals Holding, Inc. | Clonidine preparations |
US20030077301A1 (en) | 1999-12-16 | 2003-04-24 | Maibach Howard I. | Topical pharmaceutical composition for the treatment of inflammatory dermatoses |
US6294553B1 (en) | 2000-02-15 | 2001-09-25 | Allergan Sales, Inc. | Method for treating ocular pain |
US6284765B1 (en) | 2000-04-27 | 2001-09-04 | The University Of North Texas Health Science Center At Fort Worth | (+) naloxone and epinephrine combination therapy |
US6444681B1 (en) | 2000-06-09 | 2002-09-03 | The Ohio State University Research Foundation | Methods and compositions for treating Raynaud's Phenomenon and scleroderma |
US6468989B1 (en) | 2000-07-13 | 2002-10-22 | Dow Pharmaceutical Sciences | Gel compositions containing metronidazole |
CA2402405C (en) | 2000-07-14 | 2008-02-12 | Allergan Sales, Inc. | Compositions containing alpha-2-adrenergic agonist components |
US6387383B1 (en) | 2000-08-03 | 2002-05-14 | Dow Pharmaceutical Sciences | Topical low-viscosity gel composition |
US7211267B2 (en) | 2001-04-05 | 2007-05-01 | Collagenex Pharmaceuticals, Inc. | Methods of treating acne |
US20020198209A1 (en) | 2001-05-03 | 2002-12-26 | Allergan Sales Inc. | Compositions having enhanced pharmacokinetic characteristics |
TNSN02063A1 (en) | 2001-07-07 | 2005-12-23 | Egyptian Natural Oil Co Natoil | The medical effect of jojoba oil |
US7115724B2 (en) | 2001-08-22 | 2006-10-03 | Wyeth | Murine genomic polynucleotide sequence encoding a G-protein coupled receptor and methods of use therefor |
US6680062B2 (en) | 2001-10-05 | 2004-01-20 | Color Access, Inc. | Anti-irritating rosacea treatment |
US7001615B1 (en) | 2001-12-07 | 2006-02-21 | Alcon, Inc. | Sustained release ophthalmic, otic and nasal suspension |
US20040266776A1 (en) | 2003-06-25 | 2004-12-30 | Gil Daniel W. | Methods of preventing and reducing the severity of stress-associated conditions |
US7345065B2 (en) | 2002-05-21 | 2008-03-18 | Allergan, Inc. | Methods and compositions for alleviating pain |
US20040092482A1 (en) | 2002-11-07 | 2004-05-13 | Gupta Shyam K. | Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions |
US20040156873A1 (en) | 2003-02-10 | 2004-08-12 | Gupta Shyam K. | Topically Bioavailable Acne and Rosacea Treatment Compositions |
US20040220259A1 (en) | 2003-04-04 | 2004-11-04 | Yu Ruey J. | Topical treatment of dermatological disorders associated with reactive or dilated blood vessels |
AU2004241107A1 (en) | 2003-05-15 | 2004-12-02 | Cutanix Corporation | Compositions containing a combination of a pharmaceutical agent or a cosmetic agent and an oxy group-bearing aromatic aldehyde |
US8410102B2 (en) * | 2003-05-27 | 2013-04-02 | Galderma Laboratories Inc. | Methods and compositions for treating or preventing erythema |
US7439241B2 (en) | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
US20050059664A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Novel methods for identifying improved, non-sedating alpha-2 agonists |
US20050020600A1 (en) | 2003-07-23 | 2005-01-27 | Scherer Warren J. | Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists |
US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
US7285544B2 (en) | 2003-11-18 | 2007-10-23 | Bernstein Eric F | Use of nitroxides in treating skin disease |
US7812049B2 (en) | 2004-01-22 | 2010-10-12 | Vicept Therapeutics, Inc. | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
US20050196418A1 (en) | 2004-03-04 | 2005-09-08 | Yu Ruey J. | Bioavailability and improved delivery of alkaline pharmaceutical drugs |
US8529927B2 (en) | 2004-04-30 | 2013-09-10 | Allergan, Inc. | Alpha-2 agonist polymeric drug delivery systems |
CA2824612C (en) * | 2004-05-25 | 2016-08-16 | Galderma Pharma S.A. | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
US20070003622A1 (en) | 2004-12-16 | 2007-01-04 | Sovereign Pharmaceuticals, Ltd. | Diphenhydramine containing dosage form |
US7288263B2 (en) | 2004-09-13 | 2007-10-30 | Evera Laboratories, Llc | Compositions and methods for treatment of skin discoloration |
CA2593537A1 (en) | 2005-01-12 | 2006-07-20 | S.U.L.V.E. Ltd. | Methods and pharmaceutical compositions useful for treating psoriasis |
EP1861356A1 (en) | 2005-02-01 | 2007-12-05 | Icagen, Inc. | Imines as ion channel modulators |
US20070082070A1 (en) | 2005-10-11 | 2007-04-12 | Stookey Evangeline L | Treating skin disorders |
WO2007103687A2 (en) | 2006-03-01 | 2007-09-13 | Tristrata, Inc. | Composition and method for topical treatment of tar-responsive dermatological disorders |
US20070258935A1 (en) | 2006-05-08 | 2007-11-08 | Mcentire Edward Enns | Water dispersible films for delivery of active agents to the epidermis |
US9364461B2 (en) | 2006-12-21 | 2016-06-14 | Santen Sas | Process for manufacturing ophthalmic oil-in-water emulsions |
DE102006062619B4 (en) | 2006-12-29 | 2012-04-26 | Medion Diagnostics Ag | Method for the determination of minor cell populations in heterogeneous cell populations |
WO2008144399A1 (en) | 2007-05-18 | 2008-11-27 | Bausch & Lomb Incorporated | COMPLEXES COMPRISING α2-ADRENERGIC RECEPTOR AGONISTS AND COMPOSITIONS |
US20090060852A1 (en) | 2007-07-27 | 2009-03-05 | Jack Dejovin | Compounds, Formulations and Methods for Reducing Skin Wrinkles, Creasing and Sagging |
WO2009065116A1 (en) | 2007-11-16 | 2009-05-22 | Aspect Pharmaceuticals Llc | Compositions and methods for treating purpura |
AU2008341112B2 (en) * | 2007-12-21 | 2014-02-06 | Galderma S.A. | Pre-surgical treatment |
EP2090307A1 (en) | 2008-02-15 | 2009-08-19 | Bone Therapeutics | Pharmaceutical composition for the treatment or prevention of osteoarticular diseases |
EP2288355A1 (en) * | 2008-05-30 | 2011-03-02 | Fairfield Clinical Trials LLC | Method and composition for skin inflammation and discoloration |
WO2009158646A1 (en) | 2008-06-27 | 2009-12-30 | Elixir Pharmaceuticals, Inc. | Therapeutic compunds and related methods of use |
US8293742B2 (en) | 2008-08-01 | 2012-10-23 | Alpha Synergy Development, Inc. | Preferential vasoconstriction compositions and methods of use |
WO2010027349A1 (en) | 2008-09-03 | 2010-03-11 | Transdermal Innovations Inc. | Multipurpose hydrogel compositions and products |
US20100196291A1 (en) | 2009-01-30 | 2010-08-05 | Laurence Halimi | Personal care sunscreen compositions having reduced eye irritation |
JP5052558B2 (en) * | 2009-04-03 | 2012-10-17 | ロート製薬株式会社 | Gel ointment |
EP2435083A2 (en) * | 2009-05-29 | 2012-04-04 | Galderma Research & Development | Combination of adrenergic receptor agonist -1 or -2, preferably brimonidine with fillers, preferablyhyaluronic acid |
WO2011053487A1 (en) * | 2009-10-26 | 2011-05-05 | Galderma Pharma S.A. | Methods of treating or preventing acute erythema |
EP3569223A1 (en) | 2009-10-30 | 2019-11-20 | Intratus, Inc. | Methods and compositions for sustained delivery of drugs |
US8394800B2 (en) | 2009-11-19 | 2013-03-12 | Galderma Laboratories, L.P. | Method for treating psoriasis |
WO2011117377A2 (en) * | 2010-03-26 | 2011-09-29 | Galderma Research & Development | Improved methods and compositions for safe and effective treatment of erythema |
ES2730411T3 (en) | 2010-03-26 | 2019-11-11 | Galderma Res & Dev | Enhanced compositions comprising brimonidine for a safe and effective treatment of telangiectasia |
CN104288768A (en) | 2010-06-30 | 2015-01-21 | 盖尔德马研究及发展公司 | Use of alpha-adrenergic receptor agonist |
US20120101104A1 (en) | 2010-10-21 | 2012-04-26 | Galderma S.A. | Topical gel compositions and methods of use |
US8053427B1 (en) | 2010-10-21 | 2011-11-08 | Galderma R&D SNC | Brimonidine gel composition |
-
2011
- 2011-03-25 WO PCT/EP2011/054596 patent/WO2011117377A2/en active Application Filing
- 2011-03-25 PT PT117101998T patent/PT2552449T/en unknown
- 2011-03-25 DK DK11710199.8T patent/DK2552449T3/en active
- 2011-03-25 KR KR1020157010973A patent/KR20150055082A/en not_active Application Discontinuation
- 2011-03-25 CN CN201610591527.5A patent/CN106038476B/en active Active
- 2011-03-25 CA CA2792646A patent/CA2792646C/en not_active Expired - Fee Related
- 2011-03-25 HU HUE11710199A patent/HUE033143T2/en unknown
- 2011-03-25 RU RU2012145616/15A patent/RU2519676C1/en active
- 2011-03-25 KR KR1020177003732A patent/KR20170018974A/en not_active Application Discontinuation
- 2011-03-25 JP JP2013500520A patent/JP5747391B2/en active Active
- 2011-03-25 KR KR1020127027976A patent/KR101707704B1/en active IP Right Grant
- 2011-03-25 US US13/637,040 patent/US20130071489A1/en not_active Abandoned
- 2011-03-25 PL PL11710199T patent/PL2552449T3/en unknown
- 2011-03-25 AU AU2011231543A patent/AU2011231543B2/en active Active
- 2011-03-25 ES ES11710199.8T patent/ES2627405T3/en active Active
- 2011-03-25 BR BR112012024289A patent/BR112012024289A2/en not_active Application Discontinuation
- 2011-03-25 MX MX2012010824A patent/MX2012010824A/en unknown
- 2011-03-25 CN CN201180025974XA patent/CN103298472A/en active Pending
- 2011-03-25 US US13/072,096 patent/US8513247B2/en active Active
- 2011-03-25 EP EP11710199.8A patent/EP2552449B1/en active Active
-
2012
- 2012-04-26 US US13/456,976 patent/US8513249B2/en active Active
-
2013
- 2013-12-05 US US14/097,912 patent/US20140094469A1/en not_active Abandoned
-
2015
- 2015-04-06 US US14/679,598 patent/US9861631B2/en active Active
- 2015-12-14 US US14/968,104 patent/US9861632B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090061020A1 (en) | 2007-08-31 | 2009-03-05 | Theobald Klaus P | Brimonidine Compositions for Treating Erythema |
Non-Patent Citations (9)
Title |
---|
"REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY", 1995, pages: 1517 - 1518 |
"REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY", 1995, pages: 1577 - 1591,167 |
"Topical Drug Delivery Formulations", 1990, MARCEL DEKKER, INC. |
BERGE ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19 |
GHOSH, T. K. ET AL., TRANSDERMAL AND TOPICAL DRUG DELIVERY SYSTEMS, 1997 |
III ET AL.: "Encyclopedia of Pharmaceutical Technology", vol. 3, 2002, MARCEL DEKKER, article "Gels and Jellies", pages: 1327 - 1344 |
MCGHIE, JOURNAL OF THE PHARMACY SOCIETY OF WISCONSIN, May 2001 (2001-05-01) |
PENA, GEL DOSAGE FORMS: THEORY, FORMULATION, AND PROCESSING, pages 381 - 388 |
WALTERS, SURVEY OF OPHTHALMOLOGY, vol. 41, 1996, pages S19 - S26 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013010032A1 (en) * | 2011-07-14 | 2013-01-17 | Allergan, Inc. | Gel compositions of oxymetazoline and methods of use |
JP2014533271A (en) * | 2011-11-10 | 2014-12-11 | アラーガン インコーポレイテッドAllergan,Incorporated | Pharmaceutical composition for treating skin diseases and conditions comprising 7- (1H-imidazol-4-ylmethyl) -5,6,7,8-tetrahydroquinoline |
US10201535B2 (en) | 2011-11-10 | 2019-02-12 | Allergan, Inc. | Pharmaceutical compositions comprising 7-(1H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions |
WO2020044136A1 (en) * | 2018-08-29 | 2020-03-05 | Cellix Bio Private Limited | Ophthalmic compositions and methods for the treatment of eye disorders and skin diseases |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9861632B2 (en) | Methods and compositions for safe and effective treatment of erythema | |
US20170296535A1 (en) | Methods and compositions for treating or preventing erythema | |
US8916562B2 (en) | Methods and compositions for safe and effective treatment of telangiectasia | |
AU2016269419A1 (en) | Improved methods and compositions for safe and effective treatment of erythema | |
AU2015201750A1 (en) | Improved methods and compositions for safe and effective treatment of erythema |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11710199 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011231543 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2792646 Country of ref document: CA |
|
REEP | Request for entry into the european phase |
Ref document number: 2011710199 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011710199 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2012/010824 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2772/KOLNP/2012 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013500520 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2011231543 Country of ref document: AU Date of ref document: 20110325 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20127027976 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012145616 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13637040 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012024289 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012024289 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120925 |